Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTx822 is a preclinical small molecule therapeutic developed by Primal Therapies for the treatment of lower gastrointestinal inflammation. It utilizes the proprietary Selective Microbial Metabolism Regulation Technology (SMMRT) to selectively regulate gastrointestinal microbial metabolism. The agent is characterized as having prebiotic, postbiotic, and antimicrobial properties, aimed at modulating the gut microbiome to alleviate inflammatory conditions. It is currently in the discovery and formulation development stages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PTx822.